Skip to main content

Table 1 Clinical characteristics of patients with ICIs induced endocrine toxicity

From: Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

  Endocrine AEs in ICIs (6260) Endocrine AEs in other drugs (233338)
Gender
 Male 3428(54.76) 106,643(45.70)
 Female 2095(33.47) 95,425(40.90)
 Missing 737(11.77) 31,270(13.40)
Age
  < 65 2481(39.63) 91,368(39.16)
  > =65 2496(39.87) 55,099(23.61)
 Missing 1283(20.50) 86,871(37.23)
Year
 2014 116(1.85) 17,308(7.42)
 2015 59(0.94) 37,813(16.21)
 2016 944(15.08) 47,013(20.15)
 2017 1572(25.11) 62,480(26.78)
 2018 2838 (45.34) 55,743(23.89)
 2019Q1 731(11.68) 12,981(5.56)
Outcome
 Death 601(9.60) 9752(4.18)
 Life-threatening 474(7.57) 10,435(4.47)
 Disability 108(1.73) 4958(2.12)
 Hospitalization 2329(37.20) 69,842(29.93)
 Congenital anomaly 0(0.00) 102(0.04)
 Other serious 1605(25.64) 78,742(33.75)
 Required intervention 1(0.02) 50(0.02)
 Missing 1142(18.24) 59,457(25.48)
Report countries
 United States 1997(31.90) 124,384(53.31)
 Japan 1748(27.92) 14,146(6.06)
 Great Britain 181(2.89) 11,376(4.88)
 France 393(6.28) 10,258(4.40)
 Canada 62(0.99) 8741(3.75)
 Italy 116(1.85) 7922(3.40)
 Other countries 1033(16.50) 43,567(18.67)
 Missing 730(11.66) 12,944(5.55)